The Results of the PRISM (Prediction of Rejection In Sensitized patient blood saMples) Trial with a Novel Bioassay

Background kSORT, a 17 gene blood biomarker, has been retrospectively validated for detection of BPAR and immune quiescence in kidney tx. This is the first assessment of the predictive accuracy of pre and serial post-tx kSORT in a prospective clinical trial of high immunologic risk tx patients. Methods 113 kidney tx recipients, with cPRA of >50% (median 97%) were enrolled pre-tx and followed for 6 mo post-tx in the PRISM (Prediction of Rejection...